Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls
Status:
Not yet recruiting
Trial end date:
2022-10-06
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, single-dose study in adults with moderate hepatic impairment
(defined as Child-Pugh B cirrhosis) and matched healthy control participants with normal
hepatic function. All participants in both cohorts (moderate hepatic impairment and matched
healthy controls) will receive a single dose of the study drug, linerixibat. The purpose of
this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) and
safety of linerixibat.